242
Participants
Start Date
March 2, 2023
Primary Completion Date
August 31, 2027
Study Completion Date
August 31, 2027
Hydroxyurea
Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.
Ruxolitinib
Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.
Novartis Investigative Site, Orbassano
Novartis Investigative Site, Torino
Novartis Investigative Site, Alessandria
Novartis Investigative Site, Genova
Novartis Investigative Site, Milan
Novartis Investigative Site, Monza
Novartis Investigative Site, Varese
Novartis Investigative Site, Como
Novartis Investigative Site, Piacenza
Novartis Investigative Site, Padua
Novartis Investigative Site, Padua
Novartis Investigative Site, Vicenza
Novartis Investigative Site, Verona
Novartis Investigative Site, Bologna
Novartis Investigative Site, Reggio Emilia
Novartis Investigative Site, Parma
Novartis Investigative Site, Florence
Novartis Investigative Site, Pisa
Novartis Investigative Site, Ancona
Novartis Investigative Site, Bari
Novartis Investigative Site, Tricase
Novartis Investigative Site, Lecce
Novartis Investigative Site, Napoli
Novartis Investigative Site, Napoli
Novartis Investigative Site, Pagani
Novartis Investigative Site, Cosenza
Novartis Investigative Site, Reggio Calabria
Novartis Investigative Site, Palermo
Novartis Investigative Site, Palermo
Novartis Investigative Site, Catania
Novartis Investigative Site, Roma
Novartis Investigative Site, Roma
Novartis Investigative Site, Roma
Novartis Investigative Site, Terni
Novartis Investigative Site, Viterbo
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY